Birkeland, K. I., Bodegard, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., . . . Kadowaki, T. (2020). Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab.
Trích dẫn kiểu ChicagoBirkeland, Kåre I., et al. "Lower Cardiorenal Risk With Sodium‐glucose Cotransporter‐2 Inhibitors Versus Dipeptidyl Peptidase‐4 Inhibitors in Patients With Type 2 Diabetes Without Cardiovascular and Renal Diseases: A Large Multinational Observational Study." Diabetes Obes Metab 2020.
Trích dẫn MLABirkeland, Kåre I., et al. "Lower Cardiorenal Risk With Sodium‐glucose Cotransporter‐2 Inhibitors Versus Dipeptidyl Peptidase‐4 Inhibitors in Patients With Type 2 Diabetes Without Cardiovascular and Renal Diseases: A Large Multinational Observational Study." Diabetes Obes Metab 2020.